These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 21453205

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
    Calza L, Trapani F, Salvadori C, Magistrelli E, Manfredi R, Colangeli V, Di Bari MA, Borderi M, Viale P.
    Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
    [Abstract] [Full Text] [Related]

  • 3. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
    Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C, Klein D.
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):62-9. PubMed ID: 19838127
    [Abstract] [Full Text] [Related]

  • 4. Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico.
    Andrade-Fuentes K, Mata-Marín JA, López-De León JI, Manjarrez-Téllez B, Ramírez JL, Gaytan-Martínez J.
    AIDS Patient Care STDS; 2015 Apr; 29(4):181-5. PubMed ID: 25101526
    [Abstract] [Full Text] [Related]

  • 5. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
    Monteagudo-Chu MO, Chang MH, Fung HB, Bräu N.
    J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561
    [Abstract] [Full Text] [Related]

  • 6. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
    Viganò A, Zuccotti GV, Martelli L, Giacomet V, Cafarelli L, Borgonovo S, Beretta S, Rombolà G, Mora S.
    Clin Drug Investig; 2007 Oct; 27(8):573-81. PubMed ID: 17638398
    [Abstract] [Full Text] [Related]

  • 7. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
    Young B, Buchacz K, Moorman A, Wood KC, Brooks JT, HIV Outpatient Study (HOPS) Investigators.
    AIDS Patient Care STDS; 2009 Aug; 23(8):589-92. PubMed ID: 19591609
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.
    Giacomet V, Cattaneo D, Viganò A, Nannini P, Manfredini V, Ramponi G, Clementi E, Zuccotti GV.
    Pediatr Infect Dis J; 2013 Oct; 32(10):e403-5. PubMed ID: 24067562
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M, Kaplan R, Bekker LG, Little F, Myer L.
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [Abstract] [Full Text] [Related]

  • 12. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
    Maggi P, Montinaro V, Bellacosa C, Pietanza S, Volpe A, Graziano G, Strippoli GF, Angarano G.
    AIDS Patient Care STDS; 2012 Jan; 26(1):5-11. PubMed ID: 22136504
    [Abstract] [Full Text] [Related]

  • 13. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
    Kinai E, Hanabusa H.
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):387-94. PubMed ID: 19361280
    [Abstract] [Full Text] [Related]

  • 14. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
    Pradat P, Le Pogam MA, Okon JB, Trolliet P, Miailhes P, Brochier C, Maynard M, Bailly F, Zoulim F, Cotte L.
    J Viral Hepat; 2013 Sep; 20(9):650-7. PubMed ID: 23910650
    [Abstract] [Full Text] [Related]

  • 15. Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study.
    Guaraldi G, Roverato A, Giovanardi C, Ravera F, Squillace N, Orlando G, Cappelli G, Esposito R, Palella F.
    J Antimicrob Chemother; 2009 Feb; 63(2):374-9. PubMed ID: 19095683
    [Abstract] [Full Text] [Related]

  • 16. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?
    Badiou S, De Boever CM, Terrier N, Baillat V, Cristol JP, Reynes J.
    J Infect; 2006 May; 52(5):335-8. PubMed ID: 16176835
    [Abstract] [Full Text] [Related]

  • 17. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
    Cao Y, Han Y, Xie J, Cui Q, Zhang L, Li Y, Li Y, Song X, Zhu T, Li T.
    BMC Infect Dis; 2013 Jul 01; 13():301. PubMed ID: 23815472
    [Abstract] [Full Text] [Related]

  • 18. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
    Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H, Swiss HIV Cohort Study.
    Antivir Ther; 2007 Jul 01; 12(8):1165-73. PubMed ID: 18240857
    [Abstract] [Full Text] [Related]

  • 19. The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir.
    Young J, Wang Q, Fux CA, Bernasconi E, Furrer H, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC, Swiss HIV Cohort Study.
    HIV Med; 2014 Sep 01; 15(8):505-10. PubMed ID: 24641488
    [Abstract] [Full Text] [Related]

  • 20. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
    Mauss S, Berger F, Schmutz G.
    AIDS; 2005 Jan 03; 19(1):93-5. PubMed ID: 15627039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.